Dan Chen

• Understanding the different avenues of innovation of masked and conditionally active ADCs to highlight ability to reduce on-target, off-tumor toxicity
• Breaking down the principles and advantages of bispecific ADC logic gates including AND gate EGFR-cMET ADCs
• Analyzing the maturing pipeline of multispecific ADCs to set the context of how antibody-led ADC innovation will translate to the clinic

Round up the conversation from the Discovery Biology presentations in a closing panel discussion with the speakers. Make sure to come with your questions prepared as the presenters explore the risk and rationale for pursuing novel ADC targets, and the potential of bispecific ADCs to enhance tumor targeting and therapeutic index compared to traditional ADCs.